UC Irvine Scientist’s Breakthrough Study Reveals New Hope for Hair Loss Treatment

November 1, 2024

The UC Irvine Charlie Dunlop School of Biological Sciences proudly celebrates a major milestone achieved by Professor Maksim Plikus, a faculty member whose research on stem cells and tissue regeneration is transforming the field of regenerative medicine. As cofounder and Chief Scientific Officer of Amplifica Holdings Group, Inc., Professor Plikus and his team recently unveiled groundbreaking results from their clinical study on AMP-303, a potential game-changer in hair loss treatment.

The AMP-303 study marks an exciting leap forward, providing measurable improvements in hair regrowth from just one treatment cycle. For millions affected by androgenetic alopecia (AGA), the most common form of hair loss, this discovery offers new hope. “The ability to demonstrate measurable improvements in hair regrowth with just one treatment cycle of AMP-303 is a breakthrough in addressing androgenetic alopecia,” said Professor Plikus in a recent article published in the San Diego Business Journal. He underscored that for decades, advancements in hair loss treatments have been limited to just two FDA-approved options, which require daily use for months before results might appear. In contrast, AMP-303’s ability to stimulate hair regrowth with a single cycle is both efficient and transformative.

The trial’s results reveal AMP-303’s potential for longer-lasting effects. Researchers observed that subjects experienced more than a 15% increase in non-vellus hair—the thicker, darker hair type—compared to a placebo at 60 days post-treatment, with effects lasting up to 150 days. This is especially significant as the AMP-303 injection actively signals dormant hair follicles to “wake up” and start growing hair again. Professor Plikus explained the science behind the treatment, likening hair growth to a 3D printer: “Our technology works like a signal that tells the printer it’s time to start printing again.” By reactivating hair follicles, AMP-303 has the potential to address both recent and longstanding hair loss, making it a promising option for millions.

With these encouraging results, Amplifica plans to continue advancing AMP-303 through additional trials, aiming to optimize the dosage and durability of its effects. As the company prepares for future clinical trials and partnerships, it holds fast to its goal: providing science-backed solutions to patients worldwide.

The faculty, students, and staff at the Charlie Dunlop School of Biological Sciences are inspired by Professor Plikus’ dedication and innovative contributions to science. His work exemplifies the school’s mission to push scientific boundaries for the betterment of human health. As Amplifica’s journey unfolds, the school remains committed to supporting research that transforms lives and brings hope to individuals worldwide.

Learn more about the Plikus Lab.